Nouhad Husseini
Director/Board Member at DECIBEL THERAPEUTICS, INC.
Nouhad Husseini active positions
| Companies | Position | Start | End |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2010-12-31 | - |
| CHECKMATE PHARMACEUTICALS, INC. | Director/Board Member | 2022-05-30 | - |
| Corporate Officer/Principal | 2022-05-30 | - | |
| DECIBEL THERAPEUTICS, INC. | Director/Board Member | 2023-09-21 | - |
| Corporate Officer/Principal | 2023-09-21 | - |
Career history of Nouhad Husseini
Training of Nouhad Husseini
| Princeton University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistics
International
| United States | 6 |
Operational
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Nouhad Husseini
- Experience
